From: Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach
Group 1 N=46 | Ki 67 | CD8 | ER | |||
Low | High | Low | High | Negative | Positive | |
Lymphocytes | ||||||
 <20/HPF | 17 (85) | 17 (65.4) | 34 (100) | 0 (0.0) | 16 (80) | 18 (69.2) |
 >20/HPF | 3 (15) | 9 (34.6) | 0 (0.0) | 12 (100.0) | 4 (20) | 8 (30.8) |
Test of significance | χ2=2.26 P=0.13 | FET P<0.001* | χ2=0.68 P=0.41 | |||
Stroma | ||||||
 <10% | 15 (75) | 18 (69.2) | 25 (73.5) | 8 (66.7) | 16 (80) | 17 (65.4) |
 >10% | 5 (25) | 8 (30.8) | 9 (26.5) | 4 (33.3) | 4 (20) | 9 (34.6) |
Test of significance | χ2=0.186 P=0.67 | χ2=0.21 P=0.65 | χ2=1.19 P=0.27 | |||
Mitosis | ||||||
 <30/10HPF | 20 (100) | 0 | 17 (50) | 3 (25) | 12 (60) | 8 (30) |
 >30/10HPF | 0 | 26 (100) | 17 (50) | 9 (75) | 8 (40) | 18 (69.2) |
Test of significance | FET P<0.001* | χ2=2.26 P=0.13 | χ2=3.93 P=0.04* | |||
Architecture | ||||||
 SET features | 11 (55) | 17 (65.4) | 19 (55.9) | 9 (75) | 10 (50) | 18 (69.2) |
 Papillary features | 9 (45) | 9 (34.6) | 15 (44.1) | 3 (25) | 10 (50) | 8 (30.8) |
Test of significance | χ2=0.51 P=0.47 | χ2=1.36 P=0.24 | χ2=1.76 P=0.18 | |||
Treatment response | ||||||
 Regression | 4 (20.0) | 8 (30.8) | 9 (26.5) | 3 (25.0) | 5 (25.0) | 7 (26.9) |
 Progression | 16 (80.0) | 18 (69.2) | 25 (73.5) | 9 (75.0) | 15 (75.0) | 19 (73.1) |
Test of significance | χ2=0.680 P=0.51 | χ2=0.01 P=0.92 | χ2=0.02 P=0.88 | |||
Stage | ||||||
 I & II | 5 (25.0) | 4 (15.4) | 6 (17.6) | 3 (25.0) | 3 (15.0) | 6 (23.1) |
 III & IV | 15 (75.0) | 22 (84.6) | 28 (82.4) | 9 (75.0) | 17 (85.0) | 20 (76.9) |
Test of significance | χ2=0.66 P=0.42 | χ2=0.305 P=0.58 | χ2=0.469 P=0.49 | |||
Group 1 N=46 | PR | Vimentin | E Cadherin | |||
Negative | Positive | Low | High | Negative | Positive | |
Lymphocytes | ||||||
 <20/HPF | 26 (68.4) | 8 (100) | 20 (76.9) | 14 (70) | 32 (74.4) | 2 (66.7) |
 >20/HPF | 12 (31.6) | 0 (0) | 6 (23.1) | 6 (30) | 11 (25.6) | 1 (33.3) |
Test of significance | χ2=3.42 P=0.06 | χ2=0.28 P=0.59 | FET P=1.0 | |||
Stroma | ||||||
 <10% | 27 (71.1) | 6 (75) | 21 (80.8) | 12 (60) | 31 (72.1) | 2 (66.7) |
 >10% | 11 (28.9) | 2 (25) | 5 (19.2) | 8 (40) | 12 (27.9) | 1 (33.3) |
Test of significance | χ2=0.051 P=0.82 | χ2=2.41 P=0.12 | FET P=1.0 | |||
Mitosis | ||||||
 <30/10HPF | 16 (42.1) | 4 (50) | 11 (42.3) | 9 (45) | 20 (46.5) | 0 |
 >30/10HPF | 22 (57.9) | 4 (50) | 15 (57.7) | 11 (55) | 23 (53.5) | 3 (100) |
Test of significance | FET P=0.71 | χ2=0.03 P=0.86 | χ2=2.46 P=0.12 | |||
Architecture | ||||||
 SET features | 21 (55.3) | 7 (87.5) | 17 (65.4) | 11 (55) | 26 (60.5) | 2 (66.7) |
 Papillary features | 17 (44.7) | 1 (12.5) | 9 (34.6) | 9 (45) | 17 (39.5) | 1 (33.3) |
Test of significance | χ2=2.88 P=0.09 | χ2=0.51 P=0.47 | FET P=1.0 | |||
Treatment response | ||||||
 Regression | 7 (18.4) | 5 (62.5) | 5 (19.2) | 7 (35) | 9 (20.9) | 3 (100.0) |
 Progression | 31 (81.6) | 3 (37.5) | 21 (80.8) | 13 (65) | 34 (79.1) | 0 (0.0) |
Test of significance | χ2=6.66 P=0.01* | χ2=1.46 P=0.22 | FET P=0.01* | |||
Stage | ||||||
 I & II | 5 (13.2) | 4 (50.0) | 5 (19.2) | 4 (20.0) | 7 (16.3) | 2 (66.7) |
 III & IV | 33 (86.8) | 4 (50.0) | 21 (80.8) | 16 (80.0) | 36 (83.7) | 1 (33.3) |
Test of significance | FET P=0.03* | χ2=0.004 P=0.948 | FET P=0.09 |